Ignite Creation Date:
2025-12-24 @ 3:29 PM
Ignite Modification Date:
2026-02-27 @ 6:49 AM
Study NCT ID:
NCT02129192
Status:
COMPLETED
Last Update Posted:
2017-04-12
First Post:
2014-04-30
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use
Sponsor:
Boehringer Ingelheim
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2014-05
Start Date Type:
None
Primary Completion Date:
2014-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-09
Completion Date Type:
ACTUAL
First Submit Date:
2014-04-30
First Submit QC Date:
None
Study First Post Date:
2014-05-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-10-06
Results First Submit QC Date:
None
Results First Post Date:
2017-04-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2017-03-01
Last Update Post Date:
2017-04-12
Last Update Post Date Type:
ACTUAL